Monday, July 26

Fase I

ensayos, Fase I, Noticias, pruebas, Reino Unido, Salud, SIDA, Universidad de Oxford, vacuna, vih

Oxford University Starts HIV Vaccine Trials | Digital Trends Spanish

Researchers at the University of Oxford began phase I trials of a novel vaccine targeting a "wide range" of HIV variants. The HIV-CORE 0052 trial is part of the European AIDS Vaccine Initiative, and will involve 13 healthy, HIV-negative adults between 18 and 65 years of age, who are not considered to be at high risk of infection. Thus, participants will receive a dose of the vaccine, known as HIVconsvC, followed by another booster dose at four weeks. How does it work? Unlike other vaccine candidates, HIVconsvX is designed to induce immune system T lymphocytes and target highly conserved and vulnerable regions of HIV. “An effective vaccine against HIV has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy both in HIV-negative ind...